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ABSTRACT
GM1 gangliosidosis is a lysosomal storage disorder caused by deficiency of -galactosidase. It is mainly char-
acterized by progressive neurodegeneration, and in its most severe infantile form, it leads to death before the
age of 4. The GLB1 gene gives rise to two alternatively spliced mRNAs that encode the -galactosidase and
the elastin binding protein (EBP). The diagnosis of two patients with the infantile form of GM1 gangliosido-
sis and 11 carriers in a small mountainous village in Cyprus prompted us to carry out a study in order to es-
tablish the frequency of carriers in the village and identify the mutations involved. Carrier detection was ini-
tially based on the measurement of -galactosidase activity in leucocytes. Among 85 random samples from
the village, 10 were classified as carriers. Sequencing of the GLB1 gene in a Cypriot patient identified the
missense mutation c.1445GA (p.Arg482His) in the homozygous state. Seven of the 10 carriers identified us-
ing the enzyme assay were found to carry the same mutation by NspI restriction enzyme analysis. The three
individuals who were negative for the c.1445GA had borderline enzyme results and were probably wrongly
classified as carriers. The frequency of GM1 gangliosidosis carriers in this village is approximately 8% (1:12).
Western blot analysis showed a marked decrease of the 64-kDa mature form of the enzyme protein and a sim-
ilar reduction of the 67-kDa EBP. Our results indicate that the c.1445GA mutation, which appears to be
responsible for all GM1 gangliosidosis alleles in this Cypriot village, affects protein conformation.
INTRODUCTION
THE GM1 GANGLIOSIDOSIS (MIM 230500) is an inborn errorof metabolism caused by the deficiency of a specific lyso-
somal hydrolase, -galactosidase (E.C 3.2.1.23), which cat-
alyzes the hydrolysis of terminal -galactose linkages in gan-
glioside GM1 and other carbohydrate-containing compounds.
The disease has been classified into three clinical forms: type
I (infantile), type II (late infantile/juvenile), and type III (adult)
(Suzuki et al., 2001). The most severe infantile form is char-
acterized by psychomotor regression by the age of 6 months,
facial and skeletal abnormalities, visceromegaly, and cherry-
red spot. Patients rarely survive for more than a few years. De-
ficiency of -galactosidase can also result in Morquio disease
type B (MIM 253010), a characteristic mucopolysaccharidosis
free of neurological symptoms (Callahan, 1999; Suzuki et al.,
2001). The incidence of GM1 gangliosidosis in most popula-
tions varies from 1:100,000 to 1:320,000 live births (Severine
et al., 1999).
The -galactosidase gene (GLB1), mapped on chromosome
3 (3p21.33), has been cloned and characterized (Oshima et al.,
1988; Morreau et al., 1989). The gene contains 16 exons and
encodes a precursor protein of approximately 70-kDa, which is
co-translationally modified into a glycosylated form of 85-kDa
and processed in lysosomes into a 64-kDa mature enzyme
(d’Azzo et al., 1982; Nanba et al., 1988).
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The GLB1 gene gives rise to two alternatively spliced 
mRNAs: a transcript of 2.5 kb, encoding the lysosomal enzyme,
and a transcript of 2.0kb, encoding the elastin binding protein
(EBP), which is localized on the cell surface (Hinek, 1996; Priv-
itera et al., 1998). Both the -galactosidase and the EBP form
complexes with protective protein cathepsin A and alpha neu-
raminidase.
A total of 49 mutations have been reported http://uwcmm/
1s.uwcm.ac.uk/uwcm/mg/search/119987.html. Five common
mutations have been correlated with different clinical pheno-
types: The Arg482His mutation detected in Italian patients cor-
related with infantile GM1 gangliosidosis and so did the muta-
tion Arg208Cys detected in American patients. The Arg201Cys
mutation detected in Japanese patients correlated with juvenile
GM1 gangliosidosis, whereas the Ile51Thr mutation, also found
in Japanese patients, correlated with adult GM1 gangliosidosis.
The Trp273Leu mutation found in Caucasian patients correlated
with Morquio B disease (Suzuki et al., 2001).
Two patients with the classical, infantile form of GM1 gan-
gliosidosis were diagnosed in two different families in Cyprus
in 1992. Both cases came from the village of Pelendri, which
is located in a mountainous area of the island. The fathers of
the patients are first cousins. Prior to this study, 29 persons from
this village were examined for carrier status of the disease, and
11 of them were found to be carriers. This relatively high num-
ber of carriers prompted us to initiate an epidemiological study
in order to establish the frequency of the mutant allele in the
village. A total of 104 volunteers were screened for carrier sta-
tus. The screening was initially based on the measurement of
-galactosidase activity in leucocytes. Molecular studies were
performed in order to identify the mutations involved, and ex-
pression studies followed on the identified mutation. 
MATERIALS AND METHODS
Subjects
Patient 1 was a boy, the first child of young, healthy, unre-
lated parents. He had coarse dysmorphic features, psychomo-
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tor delay, and edema of the eyes, limbs, and scrotum. At 9
months of age, he could not concentrate or fix his eyes and did
not reach out for objects. There were no focal neurological find-
ings. He also had mild hepatosplenomegaly, and hypertonia of
upper and lower limbs. The diagnosis was established by mea-
suring -galactosidase activity in leucocytes, which was found
to be 5 nmol/hr/mg protein (normal, 163–378 nmol/hr/mg pro-
tein). The family history revealed that the mother’s grandmother
gave birth to six children, five of whom died at the age of 1–2
years.
Patient 2 was also a boy, the first child of the family. The
parents are third cousins. He presented with hypertonia since
birth and developed edema of the face, eyes, and lower limbs.
His psychomotor development was delayed, and he had a mildly
coarse face. The diagnosis was established by measuring -
galactosidase activity in leucocytes, which was found to be 4
nmol/hr/mg protein (normal, 163–378 nmol/hr/mg protein).
The aborted affected fetus of a couple who had undergone
prenatal diagnosis for GM1 gangliosidosis at 12 weeks of preg-
nancy was used to establish a fibroblast cell line. The -galac-
tosidase activity in the chorionic villi of this fetus was 1.5
nmol/hr/mg protein (normal, 116–893 nmol/hr/mg protein).
In order to establish a reference range for leucocyte -galac-
tosidase activity in the Cypriot population, 102 apparently
healthy individuals, originating from various districts of the is-
land (52 men and 50 women, mean age 36 years old), were ex-
amined after giving their informed consent.
In order to establish the frequency of the mutant allele, a total
of 104 volunteers from the village of Pelendri were examined af-
ter giving their informed consent. Of these, 54 were men and 50
were women, aged 20–80 (mean age, 38 years old). Samples from
the volunteers were collected on three different occasions during
organized visits to the village. A talk on the subject by a geneti-
cist preceeded the blood collection. All volunteers were asked to
fill in a questionnaire in order to ascertain whether they were re-
lated to known patients or carriers. Subjects with a blood relation
who was either affected or a carrier were considered as having a
positive family history. If more than one member of an extended
family gave blood, only the first sample was considered random;
the rest were designated as “non-random.”
FIG. 1. Restriction analysis of genomic DNA, for the identi-
fication of the c.1445GA mutation. A 203-bp fragment was
PCR-amplified, digested with NspI, electrophoresed, and stained
with ethidium bromide. Lane 6, heterozygous; lanes 3 and 4, ho-
mozygous; lanes 1, 2, and 5, normal controls. Mr, marker.
FIG. 2. Northern blot analysis of cultured skin fibroblasts
from normal control (lane 1) and GM1 gangliosidosis fetus
[c.1445GA][c.1445GA] (lane 2). Upper panel, 0.8-kb hu-
man -gal cDNA. Lower panel, the same blot hybridized with
human -actin cDNA, to confirm RNA quality and relative
loading. 
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Biochemical analysis
For enzymatic assays, the cells (leucocytes, fibroblasts, or
transfected COS-1 cells) were lysed by sonication in water. The
activity of -galactosidase was measured using the 4-methyl-
umbelliferyl--D-galactopyranoside substrate, according to
Galjaard (1980). Protein was determined as described by Smith.
(1985), using bovine serum albumin as a standard (Sigma P-
0914).
PCR amplification and sequencing
Genomic DNA was extracted from peripheral blood using
the method of Miller et al. (1988). PCR reactions for all 16 ex-
ons of the -galactosidase gene were carried out in 50-l vol-
umes containing 50 ng of genomic DNA, 50 pmol of each oli-
gonucleotide, 5.0 U of Tag polymerase (Gibco), 2.5 U pfu turbo
DNA polymerase (Stratagene), and 100 mM of each of dCTP,
dGTP, dTTP, and dATP in 2 M Tris-HCl (pH 8.8), 1 M am-
monium sulphate (Sigma A-4418), 1 M MgCl2 (Sigma M-
1028), 100% 2-mercaptoethanol (Sigma M-3148), 10 mM
EDTA pH 8.0 (Sigma E-7889), 10 mg/ml BSA (Amersham
Pharmacia cat. no. 27-8915). The amplification procedure for
every fragment started with a 30-sec denaturation step at 94°C,
followed by 30 cycles of 20-sec denaturation, 20 sec at the an-
nealing temperatures and a 20-sec extension at 70°C. After the
last cycle, the samples were incubated for 10 min at 70°C for
the final extension. The annealing time was the melting time of
the oligonucleotide primers minus 5°C. The oligonucleotides
used for PCR reactions are as published by Georgiou et al.
(2004). Control PCR reactions in which no template DNA was
added were included during each set of PCR reactions.
PCR products were run on an agarose gel (1.5–2.0% de-
pending on PCR product size), excised and purified using 
QIAquick Gel Extraction Kit (Qiagen). Approximate 30 ng of
purified amplification product were used in sequencing reac-
tions. Both strands were sequenced with the same primers used
for PCR amplification. DNA variation numbering was based on
GenBank NM-00404.1 with 1 as A of the ATG start codon
(consensus nomenclature of mutations according to Dunnen and
Antonarakis [2001]).
Restriction enzyme analysis
To examine the GA transition in codon 482 (Arg482His),
a 10-l sample containing the 203-bp PCR product from exon
14 was digested with 10 units of NspI for 1 hr at 37°C and run
on a 3% agarose gel.
Cell cultures
Human skin fibroblasts from normal controls and from an
abortus affected with GM1 gangliosidosis were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum, penicillin (10 IU/ml), and strep-
tomycin (10 IU/ml).
Northern blot analysis
Total RNA was isolated from cultured skin fibroblasts from
a normal control and from the GM1 gangliosidosis abortus, us-
ing the Rneasy Midi kit (QIAGEN). The RNA was separated
on a 1% agarose gel containing 0.6 M formaldehyde. After elec-
trophoresis, the RNA was transferred to a Zeta-probe membrane
(Bio-Rad) and immobilized by baking at 80°C for 2 hr. A 0.8-kb
length of human -gal cDNA was used as a probe. Pre-hy-
bridization and hybridization of the blot was performed using
ExpressHyp mix (CloneTech). After hybridization, subsequent
washings were performed according to the manufacturer’s pro-
tocol. The blot was re-probed with radiolabeled -actin cDNA,
after stripping the filter by boiling it for 10 min in 0.05% SDS.
Western blot analysis
For Western blotting, human skin fibroblasts from a normal
control and from the GM1 gangliosidosis abortus were har-
vested by scraping in PBS and lysed by sonication. Cell lysates
FIG. 3. Western blot analysis of cultured skin fibroblasts for
the detection of -gal protein from a GM1 gangliosidosis fetus
[c.1445GA][c.1445GA] (lane 2) and normal control (lane
1). Mr, marker (P7708S Biolabs).
FIG. 4. Western blot analysis of cultured skin fibroblasts for
the detection of elastin binding protein (EBP) in a GM1 gan-
gliosidosis fetus [c.1445GA][c.1445GA] (lane 2) and
normal control (lane 1). Mr, marker (P7708S Biolabs).
(20 g of protein) were subjected to SDS-PAGE elec-
trophoresis and transferred to a nitrocellulose membranes (Bio-
Rad, Hercules, CA). The membranes were incubated for 16 hr
with anti–-gal native antibody (prepared in Dr. d’Azzo’s lab).
The anti--galactosidase antibody was raised against a puri-
fied placental preparation of -galactosidase, and it binds the
precursor and the mature form of the enzyme. For the detec-
tion of the elastin binding protein, the membranes were incu-
bated for 16 hr with anti:Vs ALF1 antibody (Malvagia et al.,
2004). An anti-rabbit IgG (whole molecule) alkaline phospha-
tase conjugate (Sigma A-9919) was then added, and the band
was revealed using an AP conjugate substrate kit (Bio-Rad,
Hercules, CA).
Expression studies in COS-1 cells
In vitro mutagenesis of human -galactosidase cDNA was
carried out using the method of Higuchi et al. (1988) to con-
struct the mutated vectors. The mammalian expression vector
pcDx was used as a PCR template.
The primers used for the c.1445GA (p.Arg482His) were
as follows:
Lsense: 5-CATTCCTGAATGTGGGGCCCTGC-3
Ex14anti: 5-CATAGTTCACATGTCCCATGTTC-3
Ex14sense: 5-GAACATGGGACATGTGAACTATG-3
Lanti: 5-TCCCTCAAAGACACAGGCTTTCATC-3
In order to introduce the Arg482His mutation into the full-
length cDNA, fragments (1 Kb) containing the mutation of
interest were excised from PCR products by using two restric-
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tion endonucleases, each of which has only one recognition site
in the -galactosidase cDNA (Dra III and BstX1). After elec-
trophoresis in 1% agarose gels, the DNA fragments were puri-
fied with QIAquick Gel Extraction Kit (Qiagen). The pcDx vec-
tor that contained the wild-type -galactosidase cDNA was
restricted at two unique endonuclease sites to excise the corre-
sponding wild-type fragment. The fragment carrying the muta-
tion was then ligated into the plasmids.
Normal and mutant vectors were transfected into African
green monkey kidney cells, as described by Caciotti et al.
(2003). Transfected COS-1 cells were cultured, and the activ-
ity of the -galactosidase enzyme was assayed at 48 hr post-
transfection.
Immunofluorescence
Immunolocalization of -galactosidase was performed in hu-
man skin fibroblasts from a normal control and from the GM1
gangliosidosis fetus. Cells were grown on glass coverslips for
48 hr and were subsequently fixed for 10 min in 3% parafor-
maldehyde, in 0.1 M Na-Phosphate buffer pH 7.3, and perme-
abilized with 100% cold methanol at 20°C for 30 min. The
fixed cells were then washed in PBS with 0.5% BSA and 0.15 M
glycine, and incubated overnight with the primary antibody
(prepared in Dr. d’Azzo’s lab), diluted 1:100. The secondary
antibody, a green fluorescein-labeled goat-(anti-rabbit) IgG di-
luted 1:100, was then added for 1 hr. The cells were washed
three times with PBS containing 0.5 M BSA and 0.15 M
glycine, and the nuclei were stained by adding 10 l of DAPI
for 1 min. The cells were washed again three times, and they
were examined under a fluorescence microscope.
A B
FIG. 5. Immunofluorescence detection of -galactosidase in fibroblasts: normal control (A) and GM1 gangliosidosis fetus 
(B) [c.1445GA][c.1445GA]. (Fig. 5 in color can be viewed in the online version of this issue, which is available at
www.liebertpub.com)
TABLE 1. -GALACTOSIDASE ACTIVITY IN COS-1 CELLS TRANSFECTED WITH MUTANT -GALACTOSIDASE
-Galactosidase activity
nmol/hr/mg protein Percentage of wild-type
COS-1 wild type-pcDx 765 100
COS-1 Arg482His-pcDx 105 0
COS-1 not transfected 105 —
Each experiment was performed in triplicate, and the values (nmol/hr/mg protein) are the mean values.
RESULTS
The enzyme values of the 102 healthy volunteers were ana-
lyzed using the “box plot” method in order to identify any out-
liers. Two outliers were identified and discarded. The distribu-
tion of the remaining 100 values was tested for normality using
the Kolmogorov-Smirnov test and found to be normal. This al-
lowed us to use the mean  1.96 SD as the reference range,
which is 175–331 nmol/hr/mg protein. Subjects with an enzyme
activity lower than 175 nmol/hr/mg protein were designated as
carriers of GM1 gangliosidosis. According to this criterion, 10
carriers were identified among 85 random samples, two among
nine “non-random samples,” and two among 10 samples from
persons with a family history.
Sequencing of the genomic DNA of patient 1 resulted in the
identification of a previously reported missense mutation,
c.1445GA (Arg482His). The patient was homozygous for the
mutation. The mutation was confirmed by restriction analysis
using the NspI enzyme, which creates a natural restriction site.
The 203-bp PCR product is digested to 137-bp and 66-bp frag-
ments (Fig. 1). The parents of patient 2 were shown by restric-
tion analysis to be heterozygous for this mutation. The DNA
samples from the volunteers of the village were also screened
for the Arg482His mutation. Eleven out of the 14 carriers iden-
tified in the biochemical screening were positive and three were
negative for this mutation. Subjects designated as normal in the
biochemical screening were negative for the mutation.
The GM1 gangliosidosis fetus was found to be homozygous
for the Arg482His mutation. Northern blot analysis in skin fi-
broblasts from this fetus showed that the -galactosidase
mRNA was present at levels similar to those in normal fibro-
blasts (Fig. 2). Western blots of total homogenates of cultured
fibroblasts were analyzed with affinity-purified anti–-gal an-
tibodies. The amount of the 64-kDa mature form of the -galac-
tosidase enzyme is markedly reduced in the GM1 gangliosido-
sis fetus compared to the wild-type control (Fig. 3). When the
same blot was analyzed with an anti-EBP antibody, a similar
reduction in the quantity of the elastin binding protein was de-
tected in the fetus (Fig. 4). Immunocytochemical localization
of -galactosidase in skin fibroblasts from the GM1 gangliosi-
dosis fetus shows that the level of the immunodetectable en-
zyme is very low compared to a normal control (Fig. 5).
The expression studies in COS-1 cells revealed that the
Arg482His mutation abolishes the activity of -galactosidase.
The activity of the transfected cells was found to be equal to
the background activity of non-transfected cells (Table 1).
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DISCUSSION
Carrier screening using the enzyme assay resulted in the
identification of a total of 14 carriers among 104 individuals
from the village of Pelendri. Of the 104 samples, only 85 were
random, and of these 10 were found to be carriers. Using the
PCR-based test for the mutation, 11 of 14 samples character-
ized as carriers biochemically were found to have the
Arg482His missense mutation. Of the 10 carriers found in the
random group, only seven carried this mutation. The three sam-
ples that were negative for the Arg482His mutation had equiv-
ocal enzyme levels (Table 2) and were probably incorrectly
classified as carriers by the biochemical test, although the pres-
ence of a second mutation has not been excluded. Screening for
carriers of any genetic disorder using a biochemical test has the
advantage that it can potentially pick up all carriers irrespec-
tive of the mutation involved. It does, however, have the dis-
advantage that there is usually an overlap between control and
carrier ranges. This situation is evident in the results of our
study.
Based on the results of the random group only, we conclude
that there is a high frequency of GM1 gangliosidosis carriers in
the village of Pelendri, about 8.3% (95% confidence interval,
2.43–14.17%). This high frequency is most probably due to a
founder effect followed by genetic drift and/or inbreeding. Due
to its location in the mountains, the village was most probably
isolated in the past when means of transport were underdevel-
oped. A family originating from a village within 30 km of Pe-
lendri was also found to carry the Arg482His mutation. Thus,
we might expect to find this allele among people originating
from a wider area around Pelendri. The population of Pelendri
today is around 1500, but a much larger number of people orig-
inating from this village now live all over the island. Increased
frequency of GM1 gangliosidosis has been reported in other pop-
ulations. In Malta, GM1 gangliosidosis is the most common in-
herited metabolic disorder, affecting one individual per 3700 live
births, with a carrier frequency of 1:30 (Lenicker et al., 1997).
Increased incidence of GM1 gangliosidosis is also found in
South Brazil, where it reaches a value of 1:1700 live births in
Porto Alegre City (Severini et al., 1999; Silva et al., 1999).
The mutation identified in our population was first reported
in 1991 by Oshima et al. in two Italian patients with Morquio
B disease; they were compound heterozygotes for the
Arg482His and Trp273Leu mutation. The Arg482His amino
acid substitution was also reported in 1992 in one Italian pa-
tient who was homozygous and in six unrelated Italian patients
TABLE 2. -GALACTOSIDASE ACTIVITY IN LEUCOCYTES OF NORMAL SUBJECTS, 
DEFINITE CARRIERS, AND POSSIBLE CARRIERS OF GM1 GANGLIOSIDOSIS
Enzyme activity
nmol/hr/mg protein Mean SD
Control population, n  100 169–347 252.8 39.0
Definite carriersa positive for the 95–160 116.1 25.9
Arg482 His mutation, n  15
Possible carriers negative for the 159, 173, 175 — —
Arg482His mutation, n  3
aIn this group, we included four obligate carriers, the parents of patients 1 and 2.
who were heterozygous, all of Sicilian origin (Mosna et al.,
1992). More recently, a GM1 gangliosidosis patient from Cam-
pania, South Italy, who had cardiac involvement was reported
to be heterozygous for Arg482His (Morrone et al., 2000). The
Arg482His was also identified in two Australian patients of
Maltese origin (Caciotti et al., 2005). The evidence so far thus
indicates that the Arg482His mutation is common in the
Mediterranean area. It is interesting that it is the only mutation
in the -galactosidase gene found on the islands of Cyprus and
Malta. The two islands have historic connections, especially
through the Order of St. John, which had strongholds in both
islands. It is tempting to speculate that the mutation was spread
around the Mediterranean by the crusaders and the knights of
St. John. A more detailed study into the polymorphisms asso-
ciated with this mutation in the different Mediterranean popu-
lations might prove rewarding.
Our study has shown that the Arg482His mutation results in
mRNA of normal size and quantity. These results agree with
those of Mosna et al. (1992). The amount of the 64-kDa ma-
ture form of the protein is substantially decreased in the ho-
mozygote fetus as shown by Western blot analysis. To our
knowledge, this is the first time that Western blot studies were
preformed for this mutation. The immunofluorescence studies,
also performed for the first time, showed absence of -galac-
tosidase from its normal site. Based on these results, it would
be reasonable to suggest that the Arg482His mutation alters the
folding and/or affects the stability of the mature -galactosi-
dase. More direct evidence supporting this hypothesis needs to
be obtained. A comparison of the sequence at the site of the
mutation with that in other species (using the Clustal W pro-
gram, European Bioinformatics Institute) has shown that the
Arg482 is evolutionary conserved, indicating its importance for
enzyme function. When the Arg482His mutation was expressed
in COS-1 cells, the enzyme activity did not increase above the
endogenous level found in non-transfected COS-1 cells. These
results agree with those of Oshima et al. (1991) from expres-
sion studies of the Arg482His mutation in transformed human
fibroblasts.
The amount of EBP in the homozygote fetus was also de-
creased, as shown by Western blot analysis. This is expected
since EBP arises by alternative splicing of the primary Gal tran-
script, whereby exons 3, 4, and 6 are skipped, and there is a
frameshift in exon 5. The reading frame is restored at the start
of exon 7. Since the Arg482His mutation is located in exon 14,
the conformation of EBP is expected to be affected also.
In conclusion, this study has revealed a high frequency of
the Arg482His mutation (8.3%) among the people of the vil-
lage of Pelendri in Cyprus, and it has shed some light on the
possible effect of this mutation on enzyme structure and func-
tion.
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